首页> 外文期刊>Molecular brain >Cathepsin D expression level affects alpha-synuclein processing, aggregation, and toxicity in vivo
【24h】

Cathepsin D expression level affects alpha-synuclein processing, aggregation, and toxicity in vivo

机译:组织蛋白酶D的表达水平影响体内α-突触核蛋白的加工,聚集和毒性

获取原文
           

摘要

Background Elevated SNCA gene expression and intracellular accumulation of the encoded α-synuclein (aSyn) protein are associated with the development of Parkinson disease (PD). To date, few enzymes have been examined for their ability to degrade aSyn. Here, we explore the effects of CTSD gene expression, which encodes the lysosomal protease cathepsin D (CathD), on aSyn processing. Results Over-expression of human CTSD cDNA in dopaminergic MES23.5 cell cultures induced the marked proteolysis of exogenously expressed aSyn proteins in a dose-dependent manner. Unexpectedly, brain extractions, Western blotting and ELISA quantification revealed evidence for reduced levels of soluble endogenous aSyn in ctsd knock-out mice. However, these CathD-deficient mice also contained elevated levels of insoluble, oligomeric aSyn species, as detected by formic acid extraction. In accordance, immunohistochemical studies of ctsd-mutant brain from mice, sheep and humans revealed selective synucleinopathy-like changes that varied slightly among the three species. These changes included intracellular aSyn accumulation and formation of ubiquitin-positive inclusions. Furthermore, using an established Drosophila model of human synucleinopathy, we observed markedly enhanced retinal toxicity in ctsd-null flies. Conclusion We conclude from these complementary investigations that: one, CathD can effectively degrade excess aSyn in dopaminergic cells; two, ctsd gene mutations result in a lysosomal storage disorder that includes microscopic and biochemical evidence of aSyn misprocessing; and three, CathD deficiency facilitates aSyn toxicity. We therefore postulate that CathD promotes 'synucleinase' activity, and that enhancing its function may lower aSyn concentrations in vivo.
机译:背景技术SNCA基因表达升高和编码的α-突触核蛋白(aSyn)蛋白的细胞内积累与帕金森病(PD)的发展有关。迄今为止,几乎没有研究过酶降解aSyn的能力。在这里,我们探讨了编码溶酶体蛋白酶组织蛋白酶D(CathD)的CTSD基因表达对aSyn加工的影响。结果人CTSD cDNA在多巴胺能MES23.5细胞培养物中的过表达诱导了外源表达的aSyn蛋白的显着蛋白水解,呈剂量依赖性。出乎意料的是,脑提取,蛋白质印迹和ELISA定量揭示了ctsd基因敲除小鼠中可溶性内源性aSyn水平降低的证据。但是,这些CathD缺陷型小鼠也含有不溶的,寡聚的aSyn物种,如甲酸提取所检测到的。因此,对来自小鼠,绵羊和人类的ctsd突变型大脑的免疫组织化学研究表明,选择性突触核蛋白病样变化在这三个物种中略有不同。这些变化包括细胞内aSyn的积累和泛素阳性包裹体的形成。此外,使用建立的人类突触核蛋白病果蝇模型,我们观察到ctsd空果蝇的视网膜毒性显着增强。结论我们从这些补充性研究得出结论:一是CathD可有效降解多巴胺能细胞中过量的aSyn。第二,ctsd基因突变导致溶酶体贮积病,包括aSyn加工异常的微观和生化证据。第三,CathD缺乏会促进aSyn毒性。因此,我们推测CathD会促进“突触核糖核酸酶”的活性,而增强其功能可能会降低体内aSyn的浓度。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号